Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus

doi:10.12998/wjcc.v10.i20.6900

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3430)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-4) series.

Item

Count

PDF

161

WORD

HTML

1969

Figures (1-8)

305

Tables (1-4)

273

Sum=2773

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

213

Download

444

Sum=657

Jul 16, 2022 (publication date) through Jul 31, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Cases. Jul 16, 2022; 10(20): 6900-6914
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6900

Full Size Figure Download Figure

Figure 4 Protein-protein interaction network. A: The protein-protein interaction (PPI) network of 115 overlapping genes of Sanqi and Huangjing and diabetes mellitus; B: Top 10 hub genes in the PPI network. AKT1: RAC-alpha serine/threonine-protein kinase; IL6: Interleukin 6; TNF: Tumor necrosis factor; TP53: Cellular tumor antigen p53; CASP3: Caspase-3; JUN: Transcription factor AP-1; MAPK1: Mitogen-activated protein kinase 1; MMP9: Matrix metallopeptidase-9; PTGS2: Prostaglandin G/H synthase 2; EGFR: Epidermal growth factor receptor.

Citation: Cui XY, Wu X, Lu D, Wang D. Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus. World J Clin Cases 2022; 10(20): 6900-6914
URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6900.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i20.6900